PAI Joins Advocates and Medical Professionals at the U.S. Supreme Court in Defense of Mifepristone Access
For Immediate Release
Media Contact
Katie Unthank
Director of Strategic Communications
Today PAI stood alongside sexual and reproductive health advocates and champions on the steps of the Supreme Court of the United States to speak out in defense of access to mifepristone, one of two drugs most commonly used in medication abortion in the United States.
Two decades of data from the United States and global data from almost 100 countries where mifepristone is approved demonstrate that mifepristone is safe and vital to protecting women’s health. In addition, mifepristone is on the World Health Organization’s List of Essential Medicines, a document providing a list of life-saving drugs that should be available in health systems worldwide at all times.
“The Alliance for Hippocratic Medicine v. FDA is out of step with science, the consensus of the global health and medical community and the preferences of most people in the United States,” said Nabeeha Kazi Hutchins, president and CEO of PAI. “The case ultimately is not about the safety and efficacy of mifepristone or the integrity of the FDA’s decision, but instead, another thinly veiled attempt to dismantle the reproductive health and the rights, agency and autonomy of women.”
###
ABOUT PAI
PAI is a leading civil society advocacy organization dedicated to advancing universal access to SRHR across the globe. For nearly 60 years, PAI has served as a credible source of information, a strong ally to in-country partners, and an unrelenting advocate for improved and expanded SRHR at the national, regional and global levels. PAI works to advance its mission by propelling evidence-informed advocacy strategies in the United States and globally and supporting in-country CSO partners across nearly 40 low- and middle-income countries to advocate for increased access to sexual and reproductive health services and expand SRHR for all. To learn more, visit pai.org.